AprilBio Co.,Ltd. Logo

AprilBio Co.,Ltd.

Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.

397030 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
강원도 춘천시 강원대학길 1 의생명과학대학 B동 602호, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AprilBio Co., Ltd. is a clinical-stage biotechnology company that develops innovative biologic drugs. The company's operations are centered on its proprietary SAFA™ (anti-Serum Albumin Fab Associated) platform technology, a long-acting protein engineering solution. The SAFA platform utilizes an albumin binder to extend the half-life of antibody fragments, enhancing their efficacy and safety. AprilBio's research and development pipeline is focused on creating novel therapeutics, branded as SAFAbody™, primarily for the treatment of autoimmune diseases and oncology. The company aims to address unmet medical needs by advancing drug candidates through early clinical development stages for subsequent technology transfer or licensing.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for AprilBio Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Share Issue/Capital Change
전환청구권행사 (제1회차)
Korean 11.8 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.5 KB
2025-09-12 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB

Automate Your Workflow. Get a real-time feed of all AprilBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for AprilBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea 233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece MEDIC

Talk to a Data Expert

Have a question? We'll get back to you promptly.